Investee Company News

September 18, 2018 Melinta Therapeutics Names Peter Milligan as Chief Financial Officer September 7, 2018 Mycovia Pharmaceuticals Debuts with Initiation of Phase 3 Clinical Trials for Treatment of Recurrent Vulvovaginal Candidiasis September 6, 2018 Melinta Therapeutics to Host Meetings at the Morgan Stanley 16th Annual Global Healthcare Conference September 5, 2018 Poseida Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma September 5, 2018 Immunocore strengthens IP position in the field of TCR-based therapeutics August 29, 2018 Melinta Therapeutics to Present at the Rodman & Renshaw 20th Annual Global Investment Conference August 29, 2018 Poseida Therapeutics’ Clinical Update of BCMA-specific CAR-T Program Selected as a Late Breaking Presentation at the 4th Annual CAR-TCR Summit 2018 August 20, 2018 Novan Announces Promising Clinical Results with SB414 August 20, 2018 Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours August 8, 2018 Novan Provides Business Update via 10-Q, Adopts Incentive Plan and Agrees to CEO Contract August 7, 2018 Melinta Therapeutics Reports Second Quarter 2018 Financial Results August 7, 2018 Teneobio and Poseida Expand Their Partnership to Develop UniDabs™ for Advanced CAR-T Therapies July 30, 2018 Kymab Announces Promising Results from Initial Clinical Study of New Antibody KY1005 for Treatment of Autoimmune Diseases July 20, 2018 Poseida Awarded $3.99 Million CIRM Grant to Support Preclinical Development of P-PSMA-101, a T Stem Cell Memory CAR-T Therapy for Prostate Cancer July 19, 2018 Poseida Therapeutics Appoints John P. Schmid to Board of Directors July 16, 2018 Immunocore Management Change June 4, 2018 New IMCgp100-102 Data Show Durable Response and Robust Overall Survival Rate in Patients with Metastatic Uveal Melanoma May 29, 2018 Melinta Therapeutics Announces Closing of Underwritten Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock May 24, 2018 Melinta Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference May 23, 2018 Melinta Therapeutics Announces Pricing of Public Offering of Common Stock May 22, 2018 Immunocore to Present New Data from IMCgp100-102 Trial in Metastatic Uveal Melanoma at 2018 ASCO Annual Meeting May 21, 2018 Melinta Therapeutics Announces Proposed Offering of Common Stock May 17, 2018 SB208 Increases Daily Nail Growth Rate over Four Weeks of Treatment May 15, 2018 Novan Provides Update on SB414 Inflammatory Skin Disease Development Program May 8, 2018 Melinta Therapeutics Reports First Quarter 2018 Financial Results May 7, 2018 Melinta Therapeutics Receives Up to $6.2 Million from CARB-X to Advance Clinical Development of a Novel Antimicrobial to Combat Antibiotic-Resistant Bacteria May 1, 2018 Melinta Therapeutics to Report First Quarter 2018 Financial Results on May 8, 2018 April 26, 2018 Poseida Therapeutics Presents Clinical Manufacturing Method for Durable, Persistent CAR-T Stem Cell Memory Therapies at World Orphan Drug Congress USA April 23, 2018 Melinta Therapeutics Presents Results from VABOMERE TANGO II Trial at ECCMID 2018, Highlighting Outcomes in Vulnerable Patient Populations April 23, 2018 Melinta Therapeutics Presents Updates on the Pyrrolocytosine Compound RX-P2382 against ESKAPE Pathogens at ECCMID 2018